As FDA approval of the first postpartum depression drug hits the news, study looks at how infant fussiness and a baby’s level of prematurity may influence the severity of maternal depressive symptoms.
As FDA approval of the first postpartum depression drug hits the news, study looks at how infant fussiness and a baby’s level of prematurity may influence the severity of maternal depressive symptoms.